Cohen et al. [52] presented two cases of CTCL worsening after receiving ruxolitinib (a JAK1 and 2 inhibitor) for chronic GVHD treatment. Here, JAK1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.